Asensus and KARL STORZ to Market the Intelligent Surgical Unit and Co-Develop New Vision and Instrument Platforms
February 16 2023 - 6:55AM
Asensus and KARL STORZ to Market the Intelligent Surgical Unit and
Co-Develop New Vision and Instrument Platforms
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to pioneer a new era of Performance-Guided Surgery™,
today announced that the Company has entered into a Memorandum of
Understanding (“MoU”) with KARL STORZ VentureONE Pte. Ltd. (“KARL
STORZ”), a wholly owned subsidiary of KARL STORZ SE & Co. KG, a
global leader in the medical technologies industry, especially in
the area of endoscopes, medical instruments, and devices that
offers state-of-the-art technology for minimally invasive
procedures in virtually all surgical specialties. As a
solution-oriented and innovative partner, the independent
family-owned company is in close collaboration with surgeons and
health care partners around the globe to enable them to perform at
their very best every day to improve patients' lives.
The definitive agreements to be developed under the MoU will
include the following components:
o KARL STORZ intends to market
and sell Asensus’ Intelligent Surgical Unit™ (ISU™) as a standalone
device together with their IMAGE1 S™ Imaging system and OR1™
integration solution.
o The companies intend to work
together on the integration of the ISU into KARL STORZ's
laparoscopic vision systems
o The companies intend to
jointly collaborate on developing next-generation instrumentation
to be used with Asensus and KARL STORZ surgical platforms
The detailed terms are currently being negotiated, and
definitive agreements will be finalized within 90 days.
“We are thrilled to announce this MoU with KARL STORZ, a leader
in the field of advanced surgical visualization and
instrumentation,” said Anthony Fernando, Asensus Surgical President
and CEO. “By leveraging their extensive commercial network, their
leading visualization systems and longtime instrumentation
expertise, we can bring the tremendous value of augmented
intelligence offered by the ISU to operating rooms around the
world. Beyond the benefits of their commercial scale, the
co-development of new instruments will combine two unique R&D
teams at the forefront of their fields to ultimately deliver best
in class instruments to surgeons.”
Stephan Abele, Managing Director of KARL STORZ VentureONE,
highlights, “As a company, the focus of KARL STORZ has always been
advancing the way minimally invasive procedures are performed. This
partnership with Asensus is a natural fit as we share a vision for
what digital surgery, and especially laparoscopy, could be in the
future. We are very excited to bring the novel capabilities of the
ISU to our customers, and look forward to working in tandem to
bring innovative, patient-centric solutions to the market."
About KARL STORZ SE & Co. KG
The medical technology company KARL STORZ SE & Co. KG was
founded in 1945 in Tuttlingen, Germany, and is an international
leader in the world of endoscopy. Now in its third generation, the
family-owned company employs 8,300 people in 40 countries
worldwide. The company portfolio includes more than 15,000 products
for human and veterinary medicine. KARL STORZ SE & Co. KG
stands for visionary design, precision craftsmanship and clinical
effectiveness. Sales for the fiscal year 2021 amounted to 1.97
billion euros. Production sites are located in Germany, the USA,
Switzerland and Estonia. Please find more information
at: www.karlstorz.com
KARL STORZ VentureONE Pte. Ltd. is a fully owned subsidiary of
KARL STORZ SE & Co. KG headquartered in Singapore with a
business focus on robotic solutions, artificial intelligence, and
virtual reality.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the
surgeon and patient to pioneer a new era of Performance-Guided
Surgery by unlocking clinical intelligence for surgeons to enable
consistently superior outcomes and a new standard of surgery. This
builds upon the foundation of Digital Laparoscopy with the Senhance
Surgical System powered by the Intelligent Surgical Unit (ISU) to
increase surgeon control and reduce surgical variability. With the
addition of machine vision, augmented intelligence, and deep
learning capabilities throughout the surgical experience, we intend
to holistically address the current clinical, cognitive and
economic shortcomings that drive surgical outcomes and value-based
healthcare. Learn more about Performance-Guided Surgery and Digital
Laparoscopy with the Senhance Surgical System
here: www.senhance.com. Now available
for sale in the US, EU, Japan, Russia, and select other countries.
For a complete list of indications for use,
visit: www.senhance.com/indications. For
more information, visit www.asensus.com.
Forward-Looking Statements
This press release includes statements relating to the MOU with
KARL STORZ VentureONE. These statements and other statements
regarding our future plans and goals constitute "forward looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934, and
are intended to qualify for the safe harbor from liability
established by the Private Securities Litigation Reform Act of
1995. Such statements are subject to risks and uncertainties that
are often difficult to predict, are beyond our control and which
may cause results to differ materially from expectations and
include whether the companies will be able to negotiate and
finalize definitive agreements and whether the collaboration will
be successful. For a discussion of the risks and uncertainties
associated with the Company’s business, please review our filings
with the Securities and Exchange Commission (SEC), including our
Annual Report on Form 10-K for the year ended December 31, 2021,
filed with the SEC on February 28, 2022 and our other filings we
make with the SEC. You are cautioned not to place undue reliance on
these forward looking statements, which are based on our
expectations as of the date of this press release and speak only as
of the origination date of this press release. We undertake no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
INVESTOR CONTACT:
Mark Klausner or Mike Vallie, 443-213-0499invest@asensus.com
MEDIA CONTACT | ASENSUS:
Isabella Rodriguez, 708-833-1572CG LifeEmail:
irodriguez@cglife.com
MEDIA CONTACT | KARL STORZ:
Anja EbertKARL STORZ SE & Co. KGEmail:
press@karlstorz.com
Transenterix (LSE:0LG9)
Historical Stock Chart
From Jun 2024 to Jul 2024
Transenterix (LSE:0LG9)
Historical Stock Chart
From Jul 2023 to Jul 2024